Biopharmas raising money in public or private financings, including: Adma, AGTC, Dare, Inventiva, Miragen, Orphazyme, Phio, Rapt, Salarius, Tonix.

Med-tech firms raising money in public or private financings, including: Connectyx Technologies, Lunaphore Technologies, Pentixapharm, Rewalk Robotics.

Biopharmas raising money in public or private financings, including: AGTC, Arch Biopartners, Atyr, Beam, Chi-Med, Cortexyme, Kineticos, Moleculin, Pentixapharm, Sonoma, Valo.

DUBLIN – Maat Pharma SA closed an €18 million (US$19.9 million) series B round to continue development of its standardized, off-the-shelf fecal microbiota transplant (FMT) therapy, MaaT-013.

Med-tech firms raising money in public or private financings, including: Integra Lifesciences Holdings, Itamar Medical, Jenavalve Technology, Verana Health.

Biopharmas raising money in public or private financings, including: Arcutis, Beam, DBV, Ikarovec, Integra, Kezar, Phio, Rapt, Revive, Ziopharm.

Investors in small and midsized biopharma companies were certainly rewarded in 2019, with group members in the BioWorld Drug Developers index on a tear. The price-weighted index returned 40% in value thanks to a steady flow of positive regulatory and clinical trial results from the companies throughout the year. However, investors may be less impressed with the start they have made this year, with the index dipping 8.4% in January.

Med-tech firms raising money in public or private financings, including: Avisa Pharma, Aurora Spine, Benchsci, Catalent, Hinge Health, Invivo Therapeutics, Masthercell Global, Mediquo, Outset Medical.